E.U. committee rebuffs Avastin for brain cancer; Indian court lifts block on Sun-Ranbaxy deal;

@FiercePharma: Top-read special report over the long weekend: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Article | Follow @TracyStaton

@EricPFierce: ICYMI from FiercePharmaManufacturing: More woes for Indian drugmakers. Teva recalls 40,000 bottles of drugs made by Emcure over testing problems. Story | Follow @EricPFierce

@CarlyHFierce: Allergan investors want up to $200 per share from Valeant. More | Follow @CarlyHFierce

> European regulators rejected Roche's ($RHHBY) Avastin as a treatment for the form of brain cancer known as glioblastoma, saying supporting clinical data wasn't convincing. Report

> Sun Pharmaceutical is free to proceed with its buyout of its Indian generics rival, Ranbaxy Laboratories, after a domestic court lifted a stay on the deal. Report (sub. req.)

> Roche ($RHHBY) expects its diagnostic division to grow in the U.S. faster than the rest of the market, despite cuts to Medicare reimbursement rates. Report

> Sanofi ($SNY) inked a deal to promote its generics portfolio in the Middle East via a Dubai Investment pharmaceutical subsidiary, Globalpharma. Report

> The FDA approved a new drug for acute bacterial skin infections, Dalvance, made by Durata Therapeutics. Release | Report

> Inovio's ($INO) animal health subsidiary VGX has transferred its exclusive license with Inovio of its growth hormone-releasing hormone (GHRH) and animal DNA vaccines to South Korea's Plumbline Life Sciences. Release

Medical Device News

@FierceMedDev: Roche said its surging Dx division doesn't need price reductions. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: My Uncle says "loose connection" causes most household mechanical snafus (and device recalls too, I have learned). FDA alert | Article | Follow @VarunSaxena2

@MichaelGFierce: ICYMI from FierceDrugDelivery: Smallest, fastest nanomotor moves drugs and releases them on demand. Article | Follow @MichaelGFierce

@EmilyWFierce: Sequencing the of brewing yeasts could help brewers craft new flavors of beer. NYT story | Follow @EmilyWFierce

> Sleep apnea startup banks $11M for ultrasmall device development. News

> Scientists weigh in on neuromodulation devices to treat chronic inflammatory diseases. Story

> Johnson & Johnson medical device presence growing in China. Report

Biotech News

@FierceBiotech: Thursday, @JohnCFierce and David Porter of @PennMedicine will chat, break down #ASCO2014. Follow #FierceASCO at 3:30 EST. Sponsor: @Covance. | Follow @FierceBiotech

@JohnCFierce: PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo. Article | Follow @JohnCFierce

@DamianFierce: Allergan with a very thorough Ethering of Vertex's "anemic growth driven by ... unsustainable price increases--not volume." More (PDF) | Follow @DamianFierce

@EmilyMFierce: Antigen discovery could advance malaria vaccine. Story | Follow @EmilyMFierce

> Analysis: A weakened Pfizer signals that it's prepped to wheel and deal. Editor's corner

> Bristol-Myers adds a $1.24B deal plus partnership in immuno-oncology deal frenzy. More

> Pfizer to AstraZeneca: Say goodbye to our $120B offer. Report

CRO News

> CRO Rho mounts a talent search as contracts come in. Item

> Newly merged U.K. CRO sets sail in the Cambridge biopharma hub. Report

> Clinverse partners up to bolster its trial payment software. More

> Medidata teams up with Big Pharma supergroup to de-risk trials. Article

> Parexel zeroes in on adaptive trials with its latest eClinical move. Story

Biotech IT News

> Facebook, Twitter and YouTube targeted in fake drug crackdown. Item

> Medidata, Parexel jostle for position in risk-based monitoring market. More

> Broad moves into new digs designed to encourage serendipitous discoveries. Report

> Pharma's cloud doubts prompt tech firms to add local alternatives. Article

> Takeda inks $400M IT services deal with Wipro. Story

Biotech Research News

> Database IDs new uses for existing drugs. Item

> Neurotrope, Stanford partner to treat neurological disorders with bryostatins. Report

> Antisense compound may provide new Alzheimer's treatment. Story

> Preventing biofilm formation could help fight antibiotic resistance. Article

> Antigen discovery could advance malaria vaccine. More

Pharma Manufacturing News

> Continuous manufacturing maintains slow creep toward the mainstream. Item

> WHO's links to ICH under fire amid efforts to strengthen manufacturing regulations. Report

> SeQuent continues to build Indian API assets with Arvee acquisition. Story

> Fresenius recalls hemodialysis liquid after bacteria discovery. More

> Report: FDA to inspect more Sun plants in the next few weeks. Article

And Finally... Could the Novartis ($NVS) multiple sclerosis pill Gilenya help treat PTSD? It helped traumatized mice, a new study shows. Report

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.